In light of the phenotypes of the global transgenic knockout of Nhe1 on the increased excitability of the CNS and epilepsy (especially slow-wave epilepsy) in mice [54], it raises additional concerns about the global administration approach of NHE1 inhibitors. The gene discussed is SLC9A1; the disease is epilepsy.